Approved Treatments

Enspryng (satralizumab-mwge) is an injection therapy approved in the U.S. for adults with AQP4-related NMOSD. Given as an under-the-skin injection every four weeks after three initial loading doses, the medication is used to reduce NMOSD relapse risk. It is designed to suppress the signaling of a specific immune protein thought to contribute to NMOSD-related autoimmune attacks.

Soliris (eculizumab) is an infusion treatment approved to treat adults with NMOSD and anti-AQP4 antibodies. It is used to lower the risk of disease relapse. Administered through an infusion into the vein every other week after five initial loading doses, it works by suppressing the activation of the complement cascade, a part of the immune system that’s involved in the autoimmune attacks that drive NMOSD.

Ultomiris (ravulizumab-cwvz), Soliris’ successor, is an approved infusion medication for adults with AQP4-related NMOSD that is used to reduce relapse risk. With the same mechanism of action as Soliris, but designed to last longer in the body, the therapy is given directly into the bloodstream every eight weeks after an initial loading dose.

Uplizna (inebilizumab-cdon), given as an infusion directly into the bloodstream, is an approved therapy for adults with AQP4-related NMOSD. Administered every six months after two loading doses, the therapy works by promoting the death of antibody-producing cells, thereby reducing the risk of NMOSD relapses.